Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07102615 · ClinicalTrials.gov registry record · Phase 4
Intracervical Vasopressin
A Phase 4 study of Retained Products of Conception, sponsored by Prisma Health-Upstate.
- Recruiting
- Registry status
- Phase 4
- Development phase
- 50
- Enrollment target
- 1
- Study location
NCT07102615: Recruiting Phase 4 study of Retained Products of Conception, sponsored by Prisma Health-Upstate.
NCT07102615 is a Phase 4 study of Retained Products of Conception that is actively recruiting participants, run by Prisma Health-Upstate. The registered enrollment target is 50 participants, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (90% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07102615, a Phase 4 study of Retained Products of Conception, is actively recruiting participants, sponsored by Prisma Health-Upstate.
- RECRUITING
- Registry status
- Phase 4
- Development phase
- 50 participants
- Enrollment target
- 1
- Study location
Study Summary
This randomized study looks at whether using a medicine injected into the cervix of the uterus (intracervical), called vasopressin, helps to achieve better removal of retained products of conception (RPOC). RPOC means that after a pregnancy has ended (through miscarriage, abortion, or delivery), some parts of the pregnancy tissue, usually from the placenta or fetus, have stayed in the uterus. A hysteroscopic removal of RPOC is one type of treatment. This is a surgical procedure where a doctor uses a small camera attached to a thin tube (called a hysteroscope) to look inside the uterus. The main goal of the study is : • To add to the existing research through this study to see if the injection of intracervical vasopressin leads to improved completion rates of hysteroscopic management of RPOC. Participants will: • would be randomized to receive either vasopressin intracervical injection or a placebo injection (non-active saline) during your procedure. Information from the procedure will be collected from the participant's medical record.
Primary Outcome
There is complete removal of RPOC hysteroscopically by the end of the procedure.
Conditions Studied
Interventions
- DRUG Intracervical injection of Vasopressin
- DRUG Intracervical Injection of saline
Study Locations (1)
South Carolina
- The OB/GYN Center - Greenville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 50 participants |
| Start Date | 2025-10-30 |
| Est. Completion | 2026-12-01 |
| Phase | Phase 4 |
What NCT07102615 shows while recruiting
NCT07102615 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 50 participants, a relatively small participant target, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (90% lower).
The record links to 1 condition, with Retained Products of Conception appearing as the primary indexed condition, and to 2 interventions - of which Intracervical injection of Vasopressin is the first listed.
NCT07102615 reports a single indexed study location in South Carolina.
Frequently Asked Questions
What is clinical trial NCT07102615 about?
NCT07102615 is a clinical study titled "Intracervical Vasopressin". This randomized study looks at whether using a medicine injected into the cervix of the uterus (intracervical), called vasopressin, helps to achieve better removal of retained products of conception (RPOC). RPOC means that after a pregnancy has ended (through miscarriage, abortion, or delivery), som...
What is the current status of trial NCT07102615?
This trial is currently recruiting. It is a Phase 4 study. The enrollment target is 50 participants. The study started on 2025-10-30. Estimated completion is 2026-12-01.
What conditions does trial NCT07102615 study?
This clinical trial studies the following conditions: Retained Products of Conception.
What interventions are being tested in trial NCT07102615?
The interventions under investigation include: Intracervical injection of Vasopressin (DRUG), Intracervical Injection of saline (DRUG).
Who is sponsoring clinical trial NCT07102615?
This trial is sponsored by Prisma Health-Upstate, which has 67 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07102615 being conducted?
This trial has 1 study location across South Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT07102615's enrollment target sits among peer trials
50 1255th of 2000 higher than 679 of 2,000 other Phase 4 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00200889 · 50 participants · Early Phase 1
Mapping Auricular Vagus Nerve Circuitry
- NCT00409435 · 50 participants · Phase 2
A Study of Pyridostigmine in Postural Tachycardia Syndrome
- NCT01202305 · 50 participants
The Use of Lymph Node Biopsies to Support HIV Pathogenesis Studies
- NCT01225913 · 50 participants · Phase 4
Mechanism(s) of Airflow Limitation During Exacerbation of Asthma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI